TREATMENT OF THE PERIPHERAL T LYMPHOMAS (PTCL)
Abstract:
PTCL is a heterogeneous group of diseases, each with a disappointing rate of healing;
therapeutic progress is slow for this rare disease. Development of molecular biology techniques lead to
better knowledge of these disease subtypes regarding the pathogenesis and thus it may be obtained new
therapeutic targets. Prospective multicenter clinical trials remain critical to determine the best
therapeutic regimens that can improve the cure rate for this aggressive disease. The existence of other
comorbidities with T lymphoma gives an extremely poor prognosis requiring adaptation and
improvement of therapeutic regimens.
full text article in English (.EN) |